Description: Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Home Page: www.adicetbio.com
ACET Technical Analysis
200 Clarendon Street
Boston,
MA
02116
United States
Phone:
650 503 9095
Officers
| Name | Title |
|---|---|
| Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA | CEO, Pres & Director |
| Dr. Aya Jakobovits Ph.D. | Founder & Independent Director |
| Mr. Brian Nicholas Harvey | Chief Financial Officer |
| Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer & Sr. VP |
| Dr. Donald Healey | Chief Technology Officer |
| Dr. Blake Aftab Ph.D. | Sr. VP & Chief Scientific Officer |
| Ms. Amy Locke | Head of HR |
| Dr. Nancy L. Boman M.D., Ph.D. | Sr. VP & Chief Regulatory Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Providers & Services |
| GIC Sub-Industry: | Health Care Distributors |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3297 |
| Price-to-Sales TTM: | 13.9986 |
| IPO Date: | 2018-01-26 |
| Fiscal Year End: | June |
| Full Time Employees: | 86 |